CN112915197A - Collagen peptide, polypeptide and disease inhibitor - Google Patents
Collagen peptide, polypeptide and disease inhibitor Download PDFInfo
- Publication number
- CN112915197A CN112915197A CN202110146303.4A CN202110146303A CN112915197A CN 112915197 A CN112915197 A CN 112915197A CN 202110146303 A CN202110146303 A CN 202110146303A CN 112915197 A CN112915197 A CN 112915197A
- Authority
- CN
- China
- Prior art keywords
- collagen
- peptide
- elastin
- skin
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 54
- 102000008186 Collagen Human genes 0.000 title claims abstract description 28
- 108010035532 Collagen Proteins 0.000 title claims abstract description 28
- 229920001436 collagen Polymers 0.000 title claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 19
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 239000003112 inhibitor Substances 0.000 title claims abstract description 14
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 14
- 102000016942 Elastin Human genes 0.000 claims abstract description 41
- 108010014258 Elastin Proteins 0.000 claims abstract description 41
- 229920002549 elastin Polymers 0.000 claims abstract description 41
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 30
- 241000269851 Sarda sarda Species 0.000 claims abstract description 23
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims abstract description 15
- 235000014837 Malpighia glabra Nutrition 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241001640002 Malpighia emarginata Species 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 241000167854 Bourreria succulenta Species 0.000 claims abstract description 9
- 235000019693 cherries Nutrition 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 241000962514 Alosa chrysochloris Species 0.000 claims description 11
- 210000001367 artery Anatomy 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 230000037394 skin elasticity Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 230000005189 cardiac health Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 2
- 229920002674 hyaluronan Polymers 0.000 abstract description 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 18
- 230000037406 food intake Effects 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000003238 somatosensory effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of collagen peptide, polypeptide and disease inhibitor, in particular to a collagen peptide, polypeptide and disease inhibitor, which comprises a product formula and an extraction method, wherein the product formula consists of the following components in proportion range: the skin care product comprises 3-10 g of cod collagen peptide, 0.1-1.5 g of acerola cherry natural vitamin C and 10-250 mg of bonito elastin peptide, the effects of improving immunity, increasing collagen generation and maintaining low-level blood sugar are achieved through the added acerola cherry natural vitamin C, the heart health is favorably kept, the effects of improving skin elasticity and flexibility are achieved through the added bonito elastin peptide, the collagen and elastin have synergistic effect, and the combination of the collagen and the bonito elastin can accelerate the generation of hyaluronic acid and increase skin moisture.
Description
Technical Field
The invention relates to the technical field of collagen peptides, polypeptides and disease inhibitors, in particular to collagen peptides, polypeptides and disease inhibitors.
Background
Elastin is an elastin fiber, which expands and contracts 1.5 times. Elastin fiber exists in the whole body and has the function of stabilizing collagen fiber. The Elastin content in the artery is about 50%, the Elastin content in the lung is 20%, the Elastin content in the dermis of the skin is 2-5%, the Elastin content in the artery and dermis gradually decreases with age, which is also one of the causes of wrinkles, and the Elastin bonito Elastin structure comprises two elastins (containing 4 lysine) to form a hexagonal ring bridge structure containing 3 double bonds and having aromatic ring characteristics, called Desmosine cross-link, which provides excellent elasticity and toughness, so that the demand for collagen peptides, polypeptides and disease inhibitors is increasing.
Most of the beauty and health care preparations in the market at present lack of elastin, the elastin binds the collagen in the dermis in a cellulose mode and is interwoven with the collagen into a three-dimensional net, and the ratio of the elastin to the collagen is 1: 10; however, with age and external environment, skin elasticity and related fibers are rapidly disintegrated after 30 years of age, and lack of elastin causes diseases such as vascular dysplasia and emphysema, so collagen peptides, polypeptides and disease inhibitors have been proposed to address the above problems.
Disclosure of Invention
The present invention is directed to providing collagen peptides, polypeptides and disease inhibitors that solve the problems set forth above in the background.
In order to achieve the purpose, the invention provides the following technical scheme:
collagen peptide, polypeptide and disease inhibitor, including product formulation and extraction method, the said product formulation is made up of following component and dosage proportion range: 3-10 g of cod collagen peptide, 0.1-1.5 g of acerola cherry natural vitamin C and 10-250 mg of bonito elastin peptide.
Preferably, the bonito elastin peptide is extracted from a bonito heart artery sphere at a ratio of 10%, and the bonito heart artery sphere is extracted from a fresh bonito at a ratio of 0.05%.
Preferably, the acerola natural vitamin C is prepared by processing natural acerola into concentrated juice and then spray-drying.
Compared with the prior art, the invention has the beneficial effects that:
1. according to the invention, the effects of improving immunity, increasing collagen generation and maintaining low-level blood sugar are realized by adding the acerola cherry natural vitamin C, and the heart health is favorably maintained.
2. In the invention, the effect of improving skin elasticity and flexibility is realized by adding the skipjack elastin peptide, and the collagen and the elastin act synergistically, so that the combination of the collagen and the skipjack elastin can accelerate the generation of hyaluronic acid and increase skin moisture.
Drawings
FIG. 1 is a graph showing data of measurement of skin softness before and after taking of skipjack elastin peptide of the present invention;
FIG. 2 is a graph showing data of measurement of skin elasticity before and after taking of an elastin peptide of bonito in accordance with the present invention;
FIG. 3 is a graph showing data of skin moisture detection before and after taking skipjack elastin peptide of the present invention;
FIG. 4 is a chart of data for a practitioner's visual assessment of skin in accordance with the present invention;
FIG. 5 is a somatosensory survey of the present invention.
Detailed Description
Example 1:
referring to fig. 1-5, the present invention provides a technical solution:
collagen peptide, polypeptide and disease inhibitor, including product formulation and extraction method, the said product formulation is made up of following component and dosage proportion range: 3-10 g of cod collagen peptide, 0.1-1.5 g of acerola cherry natural vitamin C and 10-250 mg of bonito elastin peptide.
The bonito elastin peptide is extracted from a bonito heart artery ball in a proportion of 10%, the bonito heart artery ball is extracted from a fresh bonito in a proportion of 0.05%, the arrangement is favorable for extracting high-purity bonito elastin peptide, the acerola cherry natural vitamin C is prepared by processing natural acerola cherry into concentrated juice and then carrying out spray drying, and the arrangement can omit processes such as evaporation, crushing and the like, and ensures freshness. Acerola cherry has the highest content of natural vitamin C and better bioavailability
Animal studies have shown that the bioavailability of vitamin C is increased by 4-8 times with the use of vitamin C and catechins or fruit juices rich in flavonoids, thereby preventing the occurrence of sepsis. (Cotereau et al (1948). Nature,161(4093),557-
A recent human clinical study conducted on asian males compared the absorption and excretion of synthetic and natural vitamin C in 20 healthy subjects for 2 weeks. It is shown that certain components of acerola juice affect the absorption of ascorbic acid in plasma and minimize its excretion through urine. (Uchida et al, 2012).
This concludes that efficient absorption of vitamin C in plasma from acerola may promote the following health benefits: improving immunity, increasing collagen production, maintaining low blood sugar level, and promoting heart health
Experiments were conducted on the cosmetic effect of the bonito elastin peptide of the present invention and the following data and results were obtained:
experiment 1: measurement of skin softness before and after taking of skipjack elastin peptide
The measuring machine is a Cutomer MPA 580/Courage-Khazaka;
the measurement parts are the central parts of the left face, the lower auricle and the labial margin;
measuring time: before, four weeks after and 8 weeks after ingestion;
the experiment was conducted by inviting 12 persons, who took an equal amount of 100mg of bonito elastin peptide every day during the experiment, and periodically measuring the skin softness value and averaging it, as shown in fig. 1, it can be concluded that: there was a significant increase in skin softness at 8 weeks post-ingestion compared to pre-ingestion.
Experiment 2: skin elasticity test before and after taking of skipjack elastin peptide
The measuring machine is a Cutomer MPA 580/Courage-Khazaka;
the measurement parts are the central parts of the left face, the lower auricle and the labial margin;
measuring time: pre-ingestion and 4 weeks post-ingestion;
the experiment was conducted by inviting 12 persons, who took an equal amount of 100mg of bonito elastin peptide every day during the experiment, and the skin elasticity values were measured periodically and averaged, and it can be concluded with reference to fig. 2: there was a significant increase in skin elasticity at week 4 after ingestion compared to before ingestion.
Experiment 3: skin moisture detection before and after taking of skipjack elastin peptide
The measuring machine is a Cutomer CM 825/Courage-Khazaka;
the measurement parts are the top of the left zygomatic bone and the central part of the inner side of the left upper arm;
measuring time: before ingestion, 4 weeks after ingestion, and 8 weeks after ingestion;
the experiment 12 persons were invited, and the skin moisture value was periodically measured and averaged by taking an equal amount of 100mg of bonito elastin peptide daily during the experiment, and it can be concluded with reference to fig. 3: there was a significant increase in skin moisture at week 4 after ingestion compared to before ingestion.
Experiment 4: visual evaluation of skin by a medical professional
Evaluation items of skin depression, dryness and scales;
the evaluation part is the central part where the left face, the lower part of the earlobe and the lip end are connected;
evaluation time: before ingestion, 4 weeks after ingestion, and 8 weeks after ingestion;
the 12 subjects were invited to the experiment, and the same amount of 100mg of bonito elastin peptide was taken daily during the experiment, and the professional doctor 12 was periodically asked to visually evaluate the skin condition of the 12 subjects who participated in the experiment, and the evaluation scores were averaged, and it can be concluded with reference to fig. 4: the overall evaluation and skin depression improved significantly at 8 weeks post-ingestion compared to pre-ingestion. At the same time, both dryness and scaling improved significantly after week 4 post-ingestion.
Experiment 5: somatosensory survey
Survey contents including 17 questions such as "complete satisfaction", "skin condition", "skin moisture", "dryness", "wrinkles around eyes", "skin softness", "skin clarity", "skin elasticity", "skin plumpness", "skin smoothness", "skin color", "pores", "pore clogging", "skin slackness", "skin stain", "makeup", "skin itch", etc.;
investigation time: before ingestion, 4 weeks after ingestion, and 8 weeks after ingestion;
the volunteers who participated in the investigation experiment were invited to randomly draw 12 volunteers whose body feels and have the above 17 problems, and during the experiment, 100mg of bonito elastin peptide was taken daily in an equal amount, and the volunteers 12 who participated in the experiment were periodically investigated to evaluate the skin problems, and the results of the investigation can be concluded with reference to fig. 5: there were 11 items taken at 4 weeks compared to before intake, and in addition, there was a significant reduction in the remaining 4 items after 8 weeks of intake.
To summarize: the test results and visual evaluation demonstrated that daily intake of 100mg elastin improved skin conditions such as skin elasticity, skin flexibility and skin moisture. The questionnaire also found that the subject felt improvement in skin.
The principles and embodiments of the present invention are explained herein using specific examples, which are presented only to assist in understanding the method and its core concepts of the present invention. The foregoing is only a preferred embodiment of the present invention, and it should be noted that there are objectively infinite specific structures due to the limited character expressions, and it will be apparent to those skilled in the art that a plurality of modifications, decorations or changes may be made without departing from the principle of the present invention, and the technical features described above may be combined in a suitable manner; such modifications, variations, combinations, or adaptations of the invention using its spirit and scope, as defined by the claims, may be directed to other uses and embodiments.
Claims (3)
1. Collagen peptide, polypeptide and disease inhibitor, including product formulation and extraction method, characterized in that: the product formula comprises the following components in proportion range: 3-10 g of cod collagen peptide, 0.1-1.5 g of acerola cherry natural vitamin C and 10-250 mg of bonito elastin peptide.
2. The collagen peptide, polypeptide, and disease inhibitor according to claim 1, wherein: the skipjack elastin peptide is extracted from a skipjack heart artery ball at a ratio of 10%, and the skipjack heart artery ball is extracted from a fresh skipjack at a ratio of 0.05%.
3. The collagen peptide, polypeptide, and disease inhibitor according to claim 1, wherein: the acerola natural vitamin C is prepared by processing natural acerola into concentrated juice and then spray-drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110146303.4A CN112915197A (en) | 2021-02-03 | 2021-02-03 | Collagen peptide, polypeptide and disease inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110146303.4A CN112915197A (en) | 2021-02-03 | 2021-02-03 | Collagen peptide, polypeptide and disease inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112915197A true CN112915197A (en) | 2021-06-08 |
Family
ID=76167894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110146303.4A Pending CN112915197A (en) | 2021-02-03 | 2021-02-03 | Collagen peptide, polypeptide and disease inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112915197A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116268102A (en) * | 2023-03-06 | 2023-06-23 | 广东官栈营养健康科技有限公司 | Fresh stewed flower glue product with repairing effect and preparation method thereof |
-
2021
- 2021-02-03 CN CN202110146303.4A patent/CN112915197A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116268102A (en) * | 2023-03-06 | 2023-06-23 | 广东官栈营养健康科技有限公司 | Fresh stewed flower glue product with repairing effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6446120B2 (en) | A composition for improving skin containing pomegranate concentrate as an active ingredient | |
| EP2152281B1 (en) | Cosmetic use of ginseng berry extract for skin whitening | |
| US8293291B2 (en) | Methods and compositions for reducing the appearance of dynamic facial wrinkles | |
| TWI500428B (en) | Sugar-free pineapple extract, method for producing the extract, and application of the extract | |
| CN102885708B (en) | Composition for external use | |
| FR2871061A1 (en) | ACTIVE PRINCIPLE CAPABLE OF INDUCING TRANSFORMATION FROM INACTIVE TGBF-LATENT TO ACTIVE TGFB | |
| CN102014930A (en) | Compositions comprising ARNOX-inhibitors for the inhibition of reactive oxygen species | |
| JP2016088933A (en) | Age production inhibitor and application thereof | |
| CN108125244A (en) | A kind of food compositions with anti-aging whitening function and preparation method thereof | |
| KR101105542B1 (en) | Cosmetic composition for sliming | |
| CN112915197A (en) | Collagen peptide, polypeptide and disease inhibitor | |
| TWI774046B (en) | Use of solanum muricatum fermented liquid for preparing a composition for promoting skin anti-aging ability, promoting anti-glycation ability, reducing melanin content, increasing skin moisturization, reducing skin texture, reducing skin wrinkles, reducing skin redness and/or reducing fat | |
| CN111956707A (en) | Method for improving growth speed of saccharomyces cerevisiae and content of effective components in plants by using red light | |
| KR101738339B1 (en) | Composition for improving skin aging and wrinkle comprising herbal medicine mixed extract as effective component | |
| CN106720822A (en) | A kind of chocolate with invigorating the lung and benefiting vital QI effect | |
| JP7182809B2 (en) | concentration improver | |
| KR20200044307A (en) | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component | |
| US20170020805A1 (en) | Cordyceps containing topical skin care formulation | |
| CN105168092B (en) | Face cleaning composition and preparation method thereof with bioactivity and moisturizing whitening function | |
| KR101789518B1 (en) | Composition for improving skin aging and wrinkle comprising Scutellaria baicalensis and Raphanus sativus mixed extract as effective component | |
| JP2019052113A (en) | Hyaluronic acid production promoter and hyaluronic acid production promoting food | |
| JP2017132747A (en) | Age production inhibitor | |
| KR20220105891A (en) | Cosmetic composition comprising a concentrate of collagen ingredients isolated from apricot | |
| KR101738340B1 (en) | Composition for improving skin aging and wrinkle comprising Coptis teeta and Trichosanthes rosthornii mixed extract as effective component | |
| CN111700818A (en) | Wrinkle-removing and anti-aging ginseng polypeptide toning lotion and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210608 |